Why Allogene Therapeutics (ALLO) Says Its Lead Cancer Program Is Still on Track in 2026 [Yahoo! Finance]
Allogene Therapeutics, Inc. (ALLO)
Last allogene therapeutics, inc. earnings: 2/27 04:30 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
Allogene Therapeutics said on March 12, 2026, that its lead program, cemacabtagene ansegedleucel, or cema-cel, remains on track in the pivotal Phase 2 ALPHA3 trial in first-line consolidation for large B-cell lymphoma. Why Allogene Therapeutics (ALLO) Says Its Lead Cancer Program Is Still on Track in 2026 The company said the study is the first designed to test whether early, measurable residual disease-guided consolidation with cema-cel can prevent recurrence in LBCL, and that it is enrolling across more than 60 activated clinical trial sites in academic and community cancer centers, including sites outside the United States. An interim futility analysis is planned for April 2026 and will compare MRD clearance rates and early safety outcomes between the cema-cel arm and observation. The company also highlighted progress in autoimmune disease with ALLO-329, a dual CD19/CD70 AlloCAR T candidate that uses its Dagger technology to reduce or potentially eliminate conventional lymph
Show less
Read more
Impact Snapshot
Event Time:
ALLO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALLO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALLO alerts
High impacting Allogene Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALLO
News
- Allogene Therapeutics (ALLO) was upgraded by Truist Financial Corporation to "strong-buy".MarketBeat
- Allogene Therapeutics (ALLO) had its "buy" rating reaffirmed by Canaccord Genuity Group Inc.. They now have a $14.00 price target on the stock.MarketBeat
- Allogene Therapeutics (ALLO) had its price target raised by Piper Sandler from $7.00 to $8.00. They now have an "overweight" rating on the stock.MarketBeat
- Allogene Therapeutics Inc (ALLO) Q4 2025 Earnings Call Highlights: Financial Stability and ... [Yahoo! Finance]Yahoo! Finance
- Allogene Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
ALLO
Earnings
- 3/12/26 - Beat
ALLO
Sec Filings
- 4/2/26 - Form 4
- 4/1/26 - Form 144
- 3/18/26 - Form 4
- ALLO's page on the SEC website